Narrative Update on Stevanato Group Price Target
Analysts have raised their price target for Stevanato Group slightly, increasing it from $28.62 to $28.80. This change is attributed to modest improvements in projected revenue growth and profit margins, despite a higher discount rate.
What's in the News
- Stevanato Group S.p.A. maintained its 2025 revenue guidance and expects revenue in the range of €1.160 billion to €1.190 billion. (Key Developments)
- The company announced a substantial expansion of its drug delivery system manufacturing capacity by adding over 2,500 square meters of advanced production space in Bad Oeynhausen, Germany. (Key Developments)
- The new German facility features an ISO 8 cleanroom, injection molding, and automated assembly. It is integral to the production of key devices such as the Aidaptus autoinjector and Alina pen injector. (Key Developments)
Valuation Changes
- Fair Value per share has increased slightly from $28.62 to $28.80.
- The Discount Rate rose from 9.87% to 10.73%.
- The projection for Revenue Growth improved modestly from 9.22% to 9.45%.
- The estimate for Net Profit Margin edged higher, moving from 16.22% to 16.40%.
- The Future Price-to-Earnings (P/E) ratio forecast decreased marginally from 36.73x to 36.69x.
Have other thoughts on Stevanato Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.